RT Journal Article
SR Electronic
T1 Geographic variation of mutagenic exposures in kidney cancer genomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.20.23291538
DO 10.1101/2023.06.20.23291538
A1 Senkin, Sergey
A1 Moody, Sarah
A1 Díaz-Gay, Marcos
A1 Abedi-Ardekani, Behnoush
A1 Cattiaux, Thomas
A1 Ferreiro-Iglesias, Aida
A1 Wang, Jingwei
A1 Fitzgerald, Stephen
A1 Kazachkova, Mariya
A1 Vangara, Raviteja
A1 Le, Anh Phuong
A1 Bergstrom, Erik N.
A1 Khandekar, Azhar
A1 Otlu, Burçak
A1 Cheema, Saamin
A1 Latimer, Calli
A1 Thomas, Emily
A1 Atkins, Joshua Ronald
A1 Smith-Byrne, Karl
A1 Penha, Ricardo Cortez Cardoso
A1 Carreira, Christine
A1 Chopard, Priscilia
A1 Gaborieau, Valérie
A1 Keski-Rahkonen, Pekka
A1 Jones, David
A1 Teague, Jon W.
A1 Ferlicot, Sophie
A1 Asgari, Mojgan
A1 Sangkhathat, Surasak
A1 Attawettayanon, Worapat
A1 Świątkowska, Beata
A1 Jarmalaite, Sonata
A1 Sabaliauskaite, Rasa
A1 Shibata, Tatsuhiro
A1 Fukagawa, Akihiko
A1 Mates, Dana
A1 Jinga, Viorel
A1 Rascu, Stefan
A1 Mijuskovic, Mirjana
A1 Savic, Slavisa
A1 Milosavljevic, Sasa
A1 Bartlett, John M.S.
A1 Albert, Monique
A1 Phouthavongsy, Larry
A1 Ashton-Prolla, Patricia
A1 Botton, Mariana R.
A1 Neto, Brasil Silva
A1 Bezerra, Stephania Martins
A1 Curado, Maria Paula
A1 de Cássio Zequi, Stênio
A1 Reis, Rui Manuel
A1 Faria, Eliney
A1 Menezes, Nei Soares
A1 Ferrari, Renata Spagnoli
A1 Banks, Rosamonde E.
A1 Vasudev, Naveen S.
A1 Zaridze, David
A1 Mukeriya, Anush
A1 Shangina, Oxana
A1 Matveev, Vsevolod
A1 Foretova, Lenka
A1 Navratilova, Marie
A1 Holcatova, Ivana
A1 Hornakova, Anna
A1 Janout, Vladimir
A1 Purdue, Mark
A1 Rothman, Nathaniel
A1 Chanock, Stephen J.
A1 Ueland, Per Magne
A1 Johansson, Mattias
A1 McKay, James
A1 Scelo, Ghislaine
A1 Chanudet, Estelle
A1 Humphreys, Laura
A1 de Carvalho, Ana Carolina
A1 Perdomo, Sandra
A1 Alexandrov, Ludmil B.
A1 Stratton, Michael R.
A1 Brennan, Paul
YR 2023
UL http://medrxiv.org/content/early/2023/10/26/2023.06.20.23291538.abstract
AB International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden1. This pertains to clear cell renal cell carcinoma (ccRCC), for which obesity, hypertension, and tobacco smoking are risk factors but do not explain its geographical variation in incidence2. Some carcinogens generate somatic mutations and a complementary strategy for detecting past exposures is to sequence the genomes of cancers from populations with different incidence rates and infer underlying causes from differences in patterns of somatic mutations. Here, we sequenced 962 ccRCC from 11 countries of varying incidence. Somatic mutation profiles differed between countries. In Romania, Serbia and Thailand, mutational signatures likely caused by extracts of Aristolochia plants were present in most cases and rare elsewhere. In Japan, a mutational signature of unknown cause was found in >70% cases and <2% elsewhere. A further mutational signature of unknown cause was ubiquitous but exhibited higher mutation loads in countries with higher kidney cancer incidence rates (p-value <6 × 10−18). Known signatures of tobacco smoking correlated with tobacco consumption, but no signature was associated with obesity or hypertension suggesting non-mutagenic mechanisms of action underlying these risk factors. The results indicate the existence of multiple, geographically variable, mutagenic exposures potentially affecting 10s of millions of people and illustrate the opportunities for new insights into cancer causation through large-scale global cancer genomics.Competing Interest StatementLBA is a compensated consultant and has equity interest in io9, LLC and Genome Insight. His spouse is an employee of Biotheranostics, Inc. LBA is also an inventor of a US Patent 10,776,718 for source identification by non-negative matrix factorization. ENB and LBA declare U.S. provisional applications with serial numbers: 63/289,601; 63/269,033; and 63/483,237. LBA also declares U.S. provisional applications with serial numbers: 63/366,392; 63/367,846; 63/412,835; and 63/492,348. VM received honoraria from Ipsen, Bayer, AstraZeneca, Janssen, Astellas Pharm and MSD, and provided expert testimony to BMS, Bayer, MSD and Janssen. No other authors declare any competing interests.Funding StatementThis work was delivered as part of the Mutographs team supported by the Cancer Grand Challenges partnership funded by Cancer Research UK (C98/A24032). This work was supported by the Wellcome Trust grants 206194 and 220540/Z/20/A. The work was also partly funded by Barretos Cancer Hospital, the Public Ministry of Labor of Campinas (Research, Prevention, and Education of Occupational Cancer, 2015 to R.M.R.), and by Hospital de Clinicas de Porto Alegre (180330 to P.A.-P., M.B., B.S.N.). The work was also partly supported by the Practical Research Project for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) (JP20ck0106547h0001 to T.S.), and by the National Cancer Center Japan Research and Development Fund (2020-A-7 to A.F.). The work was also partly funded by the 1st and 2nd Faculties of Medicine, Charles University, Prague (CAGEKID to I.H.; Occupation, Environment and Kidney Cancer in Central and Eastern Europe to A.H.). The work was also partly supported by the Ministry of Health of the Czech Republic (MH CZ - DRO (MMCI, 00209805) to L.F. and M.N.). Measurement of PFAS compounds was funded by Division of Cancer Epidemiology and Genetics of the National Cancer Institute (USA). Measurement of cystatin C was funded by Cancer Research UK (C18281/A29019).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals were first obtained from each Local Research Ethics Committee and Federal Ethics Committee when applicable, as well as from the IARC Ethics Committee (IRB number: IEC Project 17-10)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWhole genome sequencing data and patient metadata are deposited in the European Genome-phenome Archive (EGA) associated with study EGAS00001003542. Aligned BAM files for all ccRCC cases included in the final analysis were deposited in dataset EGAD00001012102, variant calling files in dataset EGAD00001012222 and patient metadata in dataset EGAD00001012223. The metabolomics data are available upon request. All other data are provided in the accompanying Supplementary Tables. https://ega-archive.org/studies/EGAS00001003542 https://ega-archive.org/datasets/EGAD00001012102 https://ega-archive.org/datasets/EGAD00001012222 https://ega-archive.org/datasets/EGAD00001012223